Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a medicare population
The plaintiff accuses Novo Nordisk of failure to warn, negligence, misrepresentation, breach of warranty, and design defect
Can IGF-1 LR3 replace natural recovery methods like rest and nutrition
Dealing with competing risks in clinical trials: How to choose the primary efficacy analysis
US$ 20.96
US$ 22.82
US$ 24.14
US$ 27.37
US$ 28.22
US$ 26.56
US$ 25.63
US$ 25.26
US$ 28.39
US$ 16750.00
Sold : Login>>